Pleural Effusion: Treatment & Management

Overview

Step 1: Classify the Effusion (Light's Criteria)

Step 2: Treat the Underlying Cause

Transudative Effusions

Thoracentesis for transudates is typically diagnostic and for symptomatic relief — not primary treatment.

Step 3: Procedural Management

Diagnostic / Therapeutic Thoracentesis

• First-line procedure for most new, undiagnosed, or symptomatic effusions
• Useful for uncomplicated effusions and as a diagnostic step for complicated ones
• Not sufficient alone for pleural infection — ongoing drainage is required (Management of Empyema, p. 6)
• Remove up to 1–1.5 L per session to reduce re-expansion pulmonary edema risk
• Perform under ultrasound guidance to reduce complication rates

Tube Thoracostomy (Chest Drain)

• Required for parapneumonic effusion with any of:
  • Frank pus (empyema)
  • Positive Gram stain or culture
  • Pleural fluid pH < 7.2
  • Loculated effusion
• Small-bore drains (10–14 Fr) are as effective as large-bore for most indications and better tolerated

Intrapleural Fibrinolytics

• For complicated parapneumonic effusions / empyema with loculations
• Combination of DNase + tPA (tissue plasminogen activator) is superior to either agent alone
• Reduces need for surgical intervention

VATS / Surgical Decortication

• For empyema not resolving with drainage and fibrinolytics
• Indicated for stage III organized empyema with thick pleural peel

Step 4: Malignant Pleural Effusion (MPE) — Specific Approach

• Talc (poudrage or slurry) — most effective sclerosant; success rate ~70–80%
• Talc poudrage (via VATS) and talc slurry (via chest drain) have similar efficacy

• Tunneled catheter allowing outpatient drainage every 1–3 days
• ~50% achieve spontaneous pleurodesis after IPC placement
• Preferred in patients with short prognosis or non-expandable lung

Summary Algorithm

Pleural Effusion Detected
        ↓
Thoracentesis (diagnostic ± therapeutic)
        ↓
Transudate? → Treat underlying cause (CHF, cirrhosis, etc.)
        ↓
Exudate?
  ├── Parapneumonic / Empyema → Chest drain ± fibrinolytics ± surgery
  ├── Malignant → IPC or pleurodesis based on lung expandability
  ├── Tuberculosis → Anti-TB therapy ± corticosteroids (reduce adhesions)
  └── Other (rheumatoid, drug-induced, chylothorax) → Treat cause

Complications of Untreated / Inadequately Treated Effusion

• Fibrothorax and lung entrapment
• Empyema necessitans (chest wall extension)
• Respiratory failure
• Sepsis from infected effusion

• Always identify and treat the underlying cause
• Drain any infected collection — thoracentesis alone is insufficient for empyema
• For MPE: IPC and pleurodesis are equivalent when the lung is expandable; IPC is preferred for trapped lung
• Use ultrasound guidance for all pleural procedures to minimize complications

Autoimmune Hepatitis (AIH): Management

Background

Diagnosis

Simplified IAIHG Scoring System (2008)

• Score ≥7 = definite AIH
• Score 6 = probable AIH

Two Types

Indications for Treatment

• AST/ALT ≥ 10× ULN
• AST/ALT ≥ 3× ULN + serum globulins ≥ 2× ULN
• Bridging necrosis or multilobular necrosis on biopsy
• Symptomatic disease (jaundice, fatigue, arthralgia)

First-Line Treatment

Standard Regimens

• Combination therapy is preferred — allows lower steroid doses, reducing side effects (osteoporosis, diabetes, cushingoid features)
• Both prednisone and prednisolone are effective; prednisone is favored in most US practices
• Check TPMT (thiopurine methyltransferase) activity before starting azathioprine to identify patients at risk for myelosuppression

Budesonide (Alternative to Prednisone)

• 3 mg TID (9 mg/day) — high first-pass hepatic extraction → fewer systemic side effects
• Appropriate for non-cirrhotic patients
• Avoid in cirrhosis — extensive portosystemic shunting bypasses first-pass metabolism, negating the advantage and risking systemic toxicity

Monitoring & Endpoints of Remission

• AST/ALT < 2× ULN
• Serum IgG normalization
• Bilirubin normalization

• Resolution of interface hepatitis on biopsy (lags biochemical remission by 3–6 months)

Duration of Therapy & Withdrawal

• Treat for a minimum of 12–18 months (Harrison's, p. 9547)
• After stopping therapy, relapse rate is ≥ 50%, even after histologic improvement
• Most patients require indefinite maintenance therapy

Preventing Relapse

• Azathioprine alone (2 mg/kg/day) after prednisone cessation reduces relapse frequency
• Low-dose prednisone (≤10 mg/day) alone is also effective for maintenance
• Maintenance azathioprine is more effective at preserving remission than low-dose prednisone alone (Harrison's, p. 9547)
• In young women of childbearing age: maintenance azathioprine carries theoretical teratogenicity risk; low-dose prednisone may be preferred

Refractory / Treatment-Failure Management

Incomplete Response or Intolerance to Standard Therapy

Acute Severe AIH (AS-AIH)

• Presents with rapid-onset jaundice, coagulopathy (INR > 1.5), without pre-existing cirrhosis
• High risk of acute liver failure
• IV methylprednisolone 40–60 mg/day for 3–5 days
• If no biochemical improvement within 7 days → evaluate urgently for liver transplantation
• MELD score ≥ 28 at presentation warrants early transplant listing

Liver Transplantation

• Acute liver failure unresponsive to corticosteroids
• End-stage liver disease (decompensated cirrhosis, MELD ≥ 15–18)
• Hepatocellular carcinoma arising from AIH cirrhosis

• 5-year survival ~80–85%
• AIH can recur in the graft (~30% at 5 years) and occasionally arises de novo in transplanted livers
• Requires ongoing low-dose immunosuppression

Special Populations

Summary Algorithm

AIH Diagnosed (biopsy + scoring)
         ↓
Active disease / treatment indicated?
         ↓ Yes
Prednisone 30 mg/day + Azathioprine 50 mg/day
         ↓
Taper prednisone over weeks → maintenance
         ↓
Remission achieved?
  ├── Yes → Continue maintenance ≥ 12–18 months → attempt withdrawal
  │          └── Relapse? → Restart + indefinite azathioprine maintenance
  └── No / Intolerant → Switch to MMF or other second-line agent
         ↓
Liver failure / refractory?
         └── Liver transplant evaluation

• Prednisone + azathioprine is the cornerstone of therapy; response expected in ~80%
• Minimum 12–18 months treatment; most patients need indefinite maintenance
• Azathioprine monotherapy is the preferred maintenance strategy to preserve remission
• Budesonide is an effective steroid-sparing alternative in non-cirrhotic patients
• Relapse after withdrawal is common (≥50%) — set patient expectations accordingly